The phenoxyalkyltriazine antagonists for 5‐ht6 receptor with promising procognitive and pharmacokinetic properties in vivo in search for a novel therapeutic approach to dementia diseases

Abstract

Among the serotonin receptors, one of the most recently discovered 5‐HT6 subtype is an important protein target and its ligands may play a key role in the innovative treatment of cognitive disorders. However, none of its selective ligands have reached the pharmaceutical market yet. Re-cently, a new chemical class of potent 5‐HT6 receptor agents, the 1,3,5‐triazine‐piperazine deriva-tives, has been synthesized. Three members, the ortho and meta dichloro‐ (1,2) and the unsubstituted phenyl (3) derivatives, proved to be of special interest due to their high affinities (1,2) and selectivity (3) toward 5‐HT6 receptor.. Thus, a broader pharmacological profile for 1–3, including comprehensive screening of the receptor selectivity and drug‐like parameters in vitro as well as both, pharma-cokinetic and pharmacodynamic properties in vivo, have been investigated within this study. A comprehensive analysis of the obtained results indicated significant procognitive‐like activity to-gether with beneficial drug‐likeness in vitro and pharmacokinetics in vivo profiles for both, (RS)‐4‐ [1‐(2,3‐dichlorophenoxy)propyl]‐6‐(4‐methylpiperazin‐1‐yl)‐1,3,5‐triazin‐2‐amine (2) and (RS)‐4‐(4‐ methylpiperazin‐1‐yl)‐6‐(1‐phenoxypropyl)‐1,3,5‐triazin‐2‐amine (3), but insensibly predominant for compound 2. Nevertheless, both compounds (2 and 3) seem to be good Central Nervous System drug candidates in search for novel therapeutic approach to dementia diseases, based on the 5‐HT6 receptor target.